Trial Profile

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemsidomide (Primary) ; Dexamethasone (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors C4 Therapeutics

Most Recent Events

10 Sep 2025 Phase of the trial has been changed to phase I
10 Sep 2025 Planned End Date changed from 7 Dec 2025 to 31 Mar 2026.
10 Sep 2025 Planned primary completion date changed from 7 Sep 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com